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EThe Future Is Now
Comment on a Recent Editorial Suggesting the
Need for a New Technology in the Treatment
of DES Restenosis
In a recent editorial, John S. Douglas Jr. elegantly describes the
issue of drug-eluting stent (DES) restenosis (1). This editorial
refers to the RIBS (Restenosis Intra-Stent: Balloon Angioplasty
Versus Drug-Eluting Stent) III trial, a study whose aim was to
compare different strategies for the treatment of DES restenosis,
and whose findings revealed that choosing a different DES
provides better angiographic outcome than alternative interven-
tional treatments (2). The comments of Douglas are relevant, and
we especially agree that a longer follow-up would probably catch
more DES restenosis and that post-procedural minimal lumen is
generally smaller with balloon angioplasty than with stent implan-
tation, due to acute elastic recoil or tissue prolapse.
However, we believe that the editorial title claiming the need for
a new technology for the treatment of DES restenosis is mislead-
ing and deserves some comments. Indeed, it is already here.
Drug-eluting balloons (DEB) represent a breakthrough technol-
ogy that has found its land of conquest for the treatment of
in-stent restenosis. The advantages related to DEB use are
extremely relevant, including local drug delivery with burst pacli-
taxel release, need for short dual antiplatelet therapy, diffuse and
homogeneous rather than strut-related drug distribution, and lack
of a further metallic layer.
With regard to DES restenosis, the effectiveness of DEB was
first assessed in a small trial recently published in JACC: Cardio-
vascular Interventions that showed significantly lower late lumen
oss in patients with sirolimus-eluting stent restenosis who were
reated by DEB angioplasty rather than conventional balloon
ngioplasty (0.18  0.45 mm vs. 0.72  0.55 mm, p  0.001) (3).
ore robust evidence favoring DEB use in DES restenosis was
rovided by the PEPCAD (Paclitaxel-Eluting PTCA Balloon
atheter in Coronary Artery Disease) DES trial, which demon-
trated the superiority of a DEB strategy compared with plain
alloon angioplasty in the treatment of patients with both
aclitaxel-eluting and sirolimus-eluting stent restenosis, providing
less-than-one-half late lumen loss value (0.43  0.61 mm vs.
.03  0.77 mm, p  0.001) and almost 4 less binary restenosis
17% vs. 61%, p  0.001). Moreover, the pattern of restenosis in
he plain balloon group was focal in 72% of patients and less
omplex than in the DEB group (4).
Restenosis after DES implantation has specific morphological
atterns and tissue composition, making it particularly challenging
o treat. Although a direct comparison is not available, DEB
ngioplasty for treatment of DES restenosis seems to be associated
ith lower or at least equivalent need for reintervention when
elated to DES use. The recurrent use of a DES, however, involveshe addition of a further metallic layer and poorly known drug
ehavior.
So, given DEB sound pathophysiological premises and good
reliminary clinical results, we believe that the time of waiting for
new technology is over; we only have to give a glimpse at it on
ur shelf!
Bernardo Cortese, MD
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Reply
The letter of Drs. Cortese and Sgueglia regarding my editorial
comment (1) is very much appreciated. They appropriately call
attention to the recently published work of Rittger et al. (2), which
favorably compared paclitaxel-coated balloon angioplasty (PCBA)
with plain balloon angioplasty in the treatment of drug-eluting
stent (DES) restenosis. This is the second small randomized trial
powered to compare late lumen loss at 6-month angiography. As
noted, both studies showed quite significant reduction in late
lumen loss, restenosis, target vessel revascularization, and major
adverse cardiac events at 6 months following PCBA (2,3). These
results along with the report by Scheller et al. (4) that PCBA of
bare-metal in-stent restenosis resulted in significantly better event-
free survival out to 5 years are indeed encouraging. However, these
studies raise some questions: Can a single treatment with paclitaxel
influence outcomes months or years later? In the more resistant
DES restenosis lesion, will PCBA only delay the appearance of
restenosis with “late catch-up” occurring as has been noted with
DES and brachytherapy? Are head-to-head direct comparisons of
PCBA and second-generation DES required to guide therapy?
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Letters to the Editor1094With regard to the first question, the lipophilicity of paclitaxel, low
water solubility, and binding characteristics contribute to its
persistence in the vessel wall following PCBA with a reported
half-life of 45 days and about 1% to 2% of the dose being present
at 6 months (5). The persistence of drug in the vessel wall for this
considerable period may account for inhibition of restenosis for
months or even years. Unfortunately, the comparisons that have
been reported in DES restenosis (2,3) are only with plain balloon
angioplasty in mostly focal lesions with short follow-up. Longer
follow-up of PCBA-treated patients is required to ensure that “late
catch-up” will not occur, and direct comparisons with second-
generation DES will be essential to determine whether PCBA is
the “breakthrough” technology that is needed.
*John S. Douglas Jr.
*Andreas Gruentzig Cardiovascular Center
Emory University Hospital
Suite F6061364 Clifton Road, North East
Atlanta, Georgia 30322
E-mail: jdoug01@emory.edu
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